Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease

Sebastiaan Ten Bokkel Huinink, Vince Biemans, Marjolijn Duijvestein, Marieke Pierik, Frank Hoentjen, Rachel L West, Christien J van der Woude, Annemarie C de Vries*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)e783-e788
Number of pages6
JournalEuropean Journal of Gastroenterology & Hepatology
Volume33
Issue number1S Suppl 1
DOIs
Publication statusPublished - 1 Dec 2021

Keywords

  • Crohn's disease
  • treatment failure
  • Ustekinumab
  • MAINTENANCE THERAPY
  • MODERATE

Cite this